News

National Institute for Health and Care Excellence8h
Chronic heart failure in adults: diagnosis and management
Draft guidance consultation You can now review and comment on this draft guideline. The consultation closes on Tuesday 08 July 2025 at 5pm. In line with NICE’s commitment to incorporate technology ...
The National Institute for Health and Care Excellence2d
10 Year Health Plan empowers NICE to get patients better care, faster
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...
National Institute for Health and Care Excellence3d
1 Recommendations | Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Obecabtagene autoleucel for treating relapsed or ...
What this means in practice Obe‑cel is not required to be funded in the NHS in England to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults. It should not be used ...
National Institute for Health and Care Excellence5d
NICE newsletters and alerts
NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...
The National Institute for Health and Care Excellence13d
Harnessing digital innovation for children's mental health
In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...
National Institute for Health and Care Excellence17d
Appeal | Project documents | Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] | Guidance | NICE
Notice of Appeal Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] NICE has received 1 appeal, that falls within one or more of the two strictly ...
National Institute for Health and Care Excellence19d
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS | NICE
This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...
National Institute for Health and Care Excellence19d
Overview | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...
National Institute for Health and Care Excellence19d
Overview | Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | Guidance | NICE
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...
National Institute for Health and Care Excellence19d
4 Evaluation committee members and NICE project team | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee D, ...
National Institute for Health and Care Excellence19d
Resource impact summary report | Tools and resources | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Capacity impact The capacity impact of this topic will have been realised while the treatment has been in the Cancer Drugs Fund. So, no significant change in capacity is anticipated. Localities can ...